The PeroXeal™ packaging concept protects BASF’s Kollidon® products from atmospheric oxygen, increasing stability and ensuring consistent performance. This opens the door for entirely new applications – in particular for oxygen-sensitive APIs.
BASF Pharma Ingredients and Services
The innovative PeroXeal packaging concept sets new standards in the market by protecting BASF’s PVP-based excipients (marketed under the trade name Kollidon®) from environmental influences such as atmospheric oxygen. Thanks to the new packaging, which applies established barrier technologies to the needs of the pharmaceutical ingredient market, Kollidon’s peroxide content can be reduced to a level comparable with that of naturally-based raw materials. This significantly increases stability and ensures consistent performance – and makes Kollidon a viable alternative to cellulose when working with oxygen-sensitive ingredients.
As the packaging extends Kollidon’s retest period to up to four years, customers benefit from increased flexibility in the planning, handling and shipping of goods. Additionally, the longer shelf life helps mitigate risk and provides a greater safety margin.
The PeroXeal packaging concept is a combination of multiple film layers complemented by inert gas flushing and heat sealing. The foil comprises three distinct functional layers, each specifically designed to shield the product from environmental influences. The transparent inner lining is compatible with non-invasive NIR testing – so packaging remains airtight until the product is put to use.
A large number of Kollidon products are already available in PeroXeal packaging – at no additional cost to the customer.
Contact details
www.kollidon.com/kollidon/PeroXealconcept.aspx?pharma-ingredients@basf.com
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.